rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Kewaunee Scientific Corporation

KEQU · Nasdaq

Health CareLife-science toolsNot moving yet

KEQU stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 11.2% below that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
54% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$475K
Officials’ trades on record
0
Institutions holding
31 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$646K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months7
Buyers · sellers0 · 2
WhoDidSharesTraded
Thomas David Hull IIIPresident, CEOsold2,177at $37.507 Jan 2026filed 8 Jan 2026
Donald T. Gardner IIIChief Financial Officersold2,000at $37.576 Jan 2026filed 7 Jan 2026
Thomas David Hull IIIPresident, CEOsold629at $37.6631 Dec 2025filed 2 Jan 2026
Thomas David Hull IIIPresident, CEOsold29at $38.0030 Dec 2025filed 2 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders31+0 on the quarter
New · exited1 · 1
Reported value$42.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
NORTHERN TRUST CORPreduced · filed 13 Aug 2026238,111$8.5M-7,853−3.2%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026175,042$6.2M-2,297−1.3%
Minerva Advisors LLCadded · filed 12 Aug 2026149,410$5.3M+12,705+9.3%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026110,051$3.9M-2,462−2.2%
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.added · filed 14 Aug 2026105,545$3.7M+4,843+4.8%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 202695,311$3.4M-3,200−3.2%
De Lisle Partners LLPunchanged · filed 12 Aug 202652,626$1.9M00.0%
ROYCE & ASSOCIATES LPadded · filed 14 Aug 202649,700$1.8M+1,700+3.5%
AMERICAN CENTURY COMPANIES INCreduced · filed 12 Aug 202649,530$1.8M-210.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202624,931$886K+452+1.8%
31 Mar 2023 – 30 Jun 2026
142637Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Donald T. Gardner III Company insiderChief Financial Officer · last 30 Jun 20260 · 12
Douglas J. Batdorff Company insiderSVP, Manufacturing Operations · last 30 Jun 20260 · 3
Elizabeth D. Phillips Company insiderSVP, People & Culture · last 30 Jun 20262 · 5
Mandar Ranade Company insiderSVP, IT & Engineering · last 30 Jun 20260 · 2
Ryan S. Noble Company insiderSVP, Sales & Marketing Dev · last 30 Jun 20261 · 4
Thomas David Hull III Company insiderPresident & CEO · last 30 Jun 20260 · 23
John Jette Campbell Company insiderDirector · last 1 May 20260 · 0
Keith M. Gehl Company insiderDirector · last 1 May 20264 · 0
Margaret B. Pyle Company insiderDirector · last 26 Mar 20260 · 0
John Russell Company insiderDirector · last 7 May 20259 · 0
Kurt P. Rindoks Company insiderVP - Global Prod Development · last 26 Aug 20220 · 17
David S. Rhind Company insiderDirector · last 9 Jul 20210 · 5

Same industry

OABI OmniAbLeading+67%
TXG 10x GenomicsLeading+59%
AVTR AvantorLeading+45%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+35%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 30 Apr 202628.5%
Operating profit marginFY 2026 · to 30 Apr 20265.9%
Free cash flow marginFY 2026 · to 30 Apr 20265.2%
Return on capital employedFY 2026 · to 30 Apr 202612.9%
Cash conversionFY 2026 · to 30 Apr 2026194%
Debt to equityFY 2026 · to 30 Apr 20260.34×
Research spendFY 2026 · to 30 Apr 20260.3%
Share count trendFY 2026 · to 24 Jun 20260.2%
Cash and equivalentsFY 2026 · to 30 Apr 2026$9.9M
Free cash flowFY 2026 · to 30 Apr 2026$14.7M

Analyst forecasts

No analyst forecasts yet.